Cystaran Receives FDA Approval for Treatment of Corneal Cystine Crystals in Cystinosis Patients
Cystaran 0.44% (cysteamine ophthalmic solution;
Sigma-Tau Pharmaceuticals, Inc.), a topical ophthalmic
therapeutic for the treatment of patients suffering
from corneal cystine crystal accumulation as a result
of cystinosis, has received FDA approval, according
to a company news release. Cysteamine is a cystinedepleting...